MarginsXMarginsX
Home › Markets › INBP

Integrated Biopharma Inc (INBP)

INBP is quoted over the counter, not listed on an exchange. Integrated Biopharma Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close · November 16, 2026
$0.1550
-8.8% on the day
1-year return
-42.6%
Market cap
$4.8M
Nano cap. From the Nov 16, 2026 close × 31.1M shares (10-Q cover page, Nov 13, 2026)
P/E and P/S
Net loss over the period · 0.1×
On trailing twelve months to June 30, 2026 (10-K)

Closes: Yahoo Finance daily closes, last bar 2026-11-16.

Profile

FieldValue
TickerINBP, quoted over the counter
SEC CIK0001016504
OTC Markets tierOTCQX (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressHillside, NJ
Incorporated inDE

Warning signs

Cash runway
Cash-flow positive
$4.5M cash at June 30, 2026
Share count, 1 year
0.0%
2025-11-10 to 2026-11-13 · +3.2% over 3 years
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-13
Cash and burn$4.5M cash; operating cash flow $310K a quarter.Report 2026-06-30
Shares outstanding31,059,610 (2026-11-13); 31,059,610 a year earlier; 30,099,610 three years earlier.Cover page 2026-11-13
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q4 2026
2026-06-30
$9.8M-$1.4M-$1.2M$4.5MNo debt tags$43.9M10-K 2026-09-25
Q3 2026
2026-03-31
$10.1M-$837K$517K$5.8MNo debt tags$48.3M10-Q 2026-05-08
Q2 2026
2025-12-31
$11.3M-$762K$617K$5.3MNo debt tags$52.1M10-Q 2026-02-11
Q1 2026
2025-09-30
$12.7M$123K$1.3M$4.7MNo debt tags$53.4M10-Q 2025-11-10
Q4 2025
2025-06-30
$14.2M-$178K$591K$3.6MNo debt tags$54.4M10-K 2026-09-25
Q3 2025
2025-03-31
$13.9M$611K$616K$3.0MNo debt tags$52.9M10-Q 2026-05-08
Q2 2025
2024-12-31
$12.6M$116K$201K$2.5MNo debt tags$52.1M10-Q 2026-02-11
Q1 2025
2024-09-30
$13.6M$259K$657K$2.3MNo debt tags$51.0M10-Q 2025-11-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32008-05-06
Latest annual report10-K2026-09-25
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEF 14A2026-10-28

Source: SEC EDGAR submissions feed, 559 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier